Background: The most widely studied type of PSMA based PET/CT is 68Ga-labeled on the small molecular inhibitor PSMA-11 (also known as PSMAHBED-CC).Objectives: To assess the diagnostic value of 68Ga-PSMAPET/CT in prostatic cancer patients referred for initial assessment and post therapeutic follow–up after prostatectomy+/- receiving adjuvant therapy. Results: 38 patients with PC performed 68Ga-PSMA PET/CT scan for initial assessment of the disease; all of them (100%) showed prostatic activity, 26 (68.4%) showed nodal activity, 18 (47.4%) showed active osseous lesions and 7 (18.4%) showed active pulmonary nodules. In conventional CT,8(21%)showed prostatic disease, 18 (47.4%) showed metastatic lymphadenopathy, 24(63.2%) showed osseous lesionsand28 showed (73.7%) pulmonary nodules. Post-prostatectomy 24patients (+/-adjuvant therapy) presented by elevated serum PSA (ranging levels: 1-2ng/ml in 8patients &>2ng/ml in 16 patients. Operative bed recurrence was detected in 16 (100%) of patients with PSA level>2ng/mlandin62.5%(5)of patients with PSA level 1-2ng/ml. 18 patients performed complementary MRI for detection of prostatic lesions and that was compatible with the 68Ga-PSMA PET/CT scan findings.Conclusions:68Ga-PSMAPET/CT has higher sensitivity than CT conventional imaging for evaluation of the primary and metastatic disease. It gets near compatible findings with mpMRI in disease localization in the prostate. It can detect tiny metastatic lymph nodes beyond the resolution of CT scans. It can detect osseous metastasis with no underlying abnormality on conventional CT scans. The likelihood of a pathogenic68Ga-PSMA PET/CT appears to be high in detection of disease recurrence with high PSA levels>2ng/ml and less at PSA levels<2ng/ml